Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial.

JAMA neurology·2026

Same author

Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Same author

The Relationship Between Placebo, Nocebo, and Cardiovascular Disease.

Cardiology clinics·2026

Same author

Reply to the Complex Etiology of Sertraline-Induced Lipid Storage Myopathy and Acquired Multiple Acyl-CoA Dehydrogenase Deficiency (MADD)-like Syndromes: Hidden Genetic Variation, Nutritional Deficiency, and Mitochondrial Vulnerability.

Muscle & nerve·2026

Same author

Sertraline-Associated Riboflavin-Responsive Lipid Storage Myopathy: Report of Two Case.

Muscle & nerve·2025

Same author

Placebo Response and Placebo Effect: What Is the Difference?

Neurologic clinics·2025

Search research articles

Related Experiment Video

Updated: Dec 14, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Refractory Chronic Immune-mediated Demyelinating Polyneuropathy.

Aziz Shaibani¹, Husam Al Sultani²

¹Nerve and Muscle Center of Texas, 6624 Fannin Street Suite 1670, Houston, TX 77030, USA; Baylor College of Medicine, Houston, TX, USA.

Neurologic Clinics

|July 25, 2020

Summary

Chronic immune-mediated demyelinating polyneuropathy (CIDP) is treatable, but some cases resist therapy due to alternative diagnoses or severe disease. This review highlights diagnostic challenges and management pitfalls for refractory CIDP.

Area of Science:

Neurology
Immunology

Background:

Chronic immune-mediated demyelinating polyneuropathy (CIDP) is a treatable neurological disorder.
Approximately 20% of CIDP cases are refractory to first-line treatments.

Keywords:

CIDP Conduction block Demyelinating MAG antibodies NF-155 Neuropathy POEMS Refractory

More Related Videos

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Related Experiment Videos

Last Updated: Dec 14, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Refractory cases often stem from alternative diagnoses or severe CIDP, complicated by diagnostic criteria ambiguity.